LSTA earnings date and last-quarter result: next report 2026-08-06, last quarter beat, P/E -1.18. Updated 2026-07-23.
Lisata Therapeutics (LSTA) Research Hub
Lisata Therapeutics (LSTA) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 1.06 USD (+6.44%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -1.18, market cap 0.02B. This hub links to the full technical, earnings and options research available for LSTA.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 1.06 USD (+6.44%) |
| 52-week range | 0.961 USD – 3.9 USD |
| Trend regime | Range |
| 14-day RSI | 37.5 (Bearish) |
| Trailing P/E | -1.18 |
| Market cap | 0.02B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-06 |
Available research for LSTA
Covered Call on LSTA: how it works, illustrative setup around the real 1.06 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on LSTA: how it works, illustrative setup around the real 1.06 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on LSTA: how it works, illustrative setup around the real 1.06 USD price, max profit/loss, breakeven and when to use it. Educational.
LSTA technical analysis: range, last 1.06 USD, RSI 37.5, 52w range 0.961 USD–3.9 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is LSTA in?
Lisata Therapeutics (LSTA) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is LSTA in an uptrend or downtrend?
As of 2026-10-26, LSTA is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is LSTA's trailing P/E ratio?
LSTA's trailing P/E is -1.18, with a market cap of 0.02B. See the earnings research page for full valuation detail.
When does LSTA next report earnings?
LSTA is next scheduled to report earnings on 2026-08-06.